These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 33462702)

  • 21. Complete Metabolic Response on Interim
    Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
    Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Neoadjuvant Chemotherapy on Axillary Lymph Node Positivity and Numbers in Breast Cancer Cases.
    Uyan M; Koca B; Yuruker S; Ozen N
    Asian Pac J Cancer Prev; 2016; 17(3):1181-5. PubMed ID: 27039745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Random start ovarian stimulation for fertility preservation appears unlikely to delay initiation of neoadjuvant chemotherapy for breast cancer.
    Letourneau JM; Sinha N; Wald K; Harris E; Quinn M; Imbar T; Mok-Lin E; Chien AJ; Rosen M
    Hum Reprod; 2017 Oct; 32(10):2123-2129. PubMed ID: 28938748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Delayed Neoadjuvant Systemic Chemotherapy on Overall Survival Among Patients with Breast Cancer.
    de Melo Gagliato D; Lei X; Giordano SH; Valero V; Barcenas CH; Hortobagyi GN; Chavez-MacGregor M
    Oncologist; 2020 Sep; 25(9):749-757. PubMed ID: 32431013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patients' experiences with decisions on timing of chemotherapy for breast cancer.
    de Ligt KM; Spronk PER; van Bommel ACM; Vrancken Peeters MTFD; Siesling S; Smorenburg CH;
    Breast; 2018 Feb; 37():99-106. PubMed ID: 29128583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant chemotherapy in stage III breast cancer.
    Alassas M; Chu Q; Burton G; Ampil F; Mizell J; Li BD
    Am Surg; 2005 Jun; 71(6):487-92. PubMed ID: 16044927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Prognostic Value of the AJCC 8th Edition Staging System for Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer.
    Kantor O; Bao J; Jaskowiak N; Yao K; Tseng J
    Ann Surg Oncol; 2020 Feb; 27(2):352-358. PubMed ID: 31376037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
    Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
    Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer.
    Mayer EL; Gropper AB; Harris L; Gold JM; Parker L; Kuter I; Come S; Najita JS; Guo H; Winer EP; Burstein HJ
    Clin Breast Cancer; 2015 Feb; 15(1):24-30. PubMed ID: 25205424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment options for locally advanced breast cancer--experience in an Asian tertiary hospital.
    Chong HY; Taib NA; Rampal S; Saad M; Bustam AZ; Yip CH
    Asian Pac J Cancer Prev; 2010; 11(4):913-7. PubMed ID: 21133600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Placental cell expression of HLA-G2 isoforms is limited to the invasive trophoblast phenotype.
    Morales PJ; Pace JL; Platt JS; Phillips TA; Morgan K; Fazleabas AT; Hunt JS
    J Immunol; 2003 Dec; 171(11):6215-24. PubMed ID: 14634138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer.
    Franceschini G; Di Leone A; Natale M; Sanchez MA; Masett R
    Ann Ital Chir; 2018; 89():290. PubMed ID: 30352955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
    Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant chemotherapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and docetaxel.
    Gu X; Jia S; Wei W; Zhang WH
    Tumour Biol; 2015 Jul; 36(7):5529-35. PubMed ID: 25682286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.
    Swisher SK; Vila J; Tucker SL; Bedrosian I; Shaitelman SF; Litton JK; Smith BD; Caudle AS; Kuerer HM; Mittendorf EA
    Ann Surg Oncol; 2016 Mar; 23(3):749-56. PubMed ID: 26511263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stage-to-stage comparison of neoadjuvant chemotherapy versus adjuvant chemotherapy in pathological lymph node positive breast cancer patients.
    Lee NK; Shin KH; Park IH; Lee KS; Ro J; Jung SY; Lee S; Kim SW; Kim TH; Kim JY; Kang HS; Cho KH
    Jpn J Clin Oncol; 2012 Nov; 42(11):995-1001. PubMed ID: 22911001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancer.
    Silva SB; Pereira AAL; Marta GN; de Barros Lima KML; de Freitas TB; Matutino ARB; de Azevedo Souza MCL; de Azevedo RGMV; de Viveiros PAH; da Silva Lima JM; Filassi JR; de Andrade Carvalho H; Piato JRM; Mano MS
    Breast; 2018 Apr; 38():39-44. PubMed ID: 29223797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breast conservation after neoadjuvant chemotherapy for stage II carcinoma of the breast.
    Schwartz GF; Meltzer AJ; Lucarelli EA; Cantor JP; Curcillo PG
    J Am Coll Surg; 2005 Sep; 201(3):327-34. PubMed ID: 16125064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01).
    Charehbili A; van de Ven S; Smit VT; Meershoek-Klein Kranenbarg E; Hamdy NA; Putter H; Heijns JB; van Warmerdam LJ; Kessels L; Dercksen M; Pepels MJ; Maartense E; van Laarhoven HW; Vriens B; Wasser MN; van Leeuwen-Stok AE; Liefers GJ; van de Velde CJ; Nortier JW; Kroep JR;
    Ann Oncol; 2014 May; 25(5):998-1004. PubMed ID: 24585721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy.
    Chien AJ; Chambers J; Mcauley F; Kaplan T; Letourneau J; Hwang J; Kim MO; Melisko ME; Rugo HS; Esserman LJ; Rosen MP
    Breast Cancer Res Treat; 2017 Aug; 165(1):151-159. PubMed ID: 28503722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.